Sign up
Pharma Capital

Regeneus takes step towards bringing Progenza osteoarthritis treatment to Europe

Progenza has been granted Advanced Therapy Medicinal Product designation.
Knee pain
The stem cell technology has been developed for the treatment of knee osteoarthritis

Regeneus Ltd (ASX:RGS) has taken a step towards bringing its Progenza osteoarthritis treatment to Europe after being granted Advanced Therapy Medicinal Product (ATMP) designation.

Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions.

The classification was granted by the European Medicines Agency’s Committee for Advanced Therapies following consultation with the European Commission.

“Important to have regulatory clarity”

John Martin, chief executive officer, said “The granting of the ATMP classification for Progenza, is a step towards bringing Progenza to Europe as a novel cell therapy treatment for osteoarthritis.

“It’s important to have regulatory clarity as we invest in the development of Progenza.”

ATMP classified products are novel regenerative therapies that combine aspects of medicine, cell biology, science and engineering.

They are presented as having properties with a view to regenerating, repairing or replacing a human tissue.

ATMPs comprise cell and gene therapies and tissue-engineered products.

10-15% of all adults over 60 are affected

The World Health Organisation estimates that 10-15% of all adults over 60 have some degree of osteoarthritis, with prevalence higher in women than men.

Given that there are few preventative and therapeutic options for osteoarthritis and that the European population is ageing, the burden of osteoarthritis is predicted to rise.

Safety trial meets primary endpoints

Results of a phase I safety trial of Progenza in knee osteoarthritis met primary endpoints of safety and tolerability.

Secondary endpoints showed a significant, rapid and sustained reduction in knee pain, and significant improvement in cartilage volume compared to placebo, with positive signs of disease modification.

Reduced inflammation and pain

The Progenza cells work by secreting cytokines, growth factors and exosomes that act in concert to reduce inflammation and pain and encourage accelerated healing and repair of damaged or diseased tissue.

Progenza is produced from expanded mesenchymal stem cells (MSCs) extracted from adipose (fat) tissue from a healthy donor who has been extensively screened.

Unlike other stem cell products, Progenza includes secretions from MSCs that improve viability and functionality of the cells during the freezing and thawing process.

Regeneus has shown that the combination of cells and secretions has a more powerful therapeutic effect than cells alone.

The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor which helps avoid the need to pool donor material and seek multiple donors.

READ: Regeneus granted key cancer treatment patent in Japan

Regeneus is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies.

These are aimed at addressing significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

READ: Regeneus shares rise as results show Sygenus gel successfully fights acne

View full RGS profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.